Who Prioritizes Innovation? R&D Spending Compared for AbbVie Inc. and Geron Corporation

Innovation in Focus: A Tale of Two Companies

In the ever-evolving landscape of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, AbbVie Inc. and Geron Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, AbbVie consistently allocated substantial resources to R&D, with expenditures peaking at approximately $8.5 billion in 2023, marking a 156% increase from 2014. In contrast, Geron Corporation's R&D spending, while growing, remained modest, reaching around $125 million in 2023, a sixfold increase from 2014. This stark difference highlights AbbVie's aggressive pursuit of innovation, investing nearly 70 times more than Geron in 2023 alone. As the biotech industry continues to advance, these spending patterns may shape the future trajectories of these companies, influencing their competitive edge and market positioning.